Immix Biopharma (IMMX) Notes Payables (2020 - 2022)

Immix Biopharma (IMMX) reported Notes Payables of $50000.0 for Q1 2022, little changed sequentially from $50000.0 in Q4 2021.

Immix Biopharma (IMMX) Notes Payables (2020 - 2022) Analysis & Trends

Immix Biopharma (IMMX) has 3 years of Notes Payables data on file, last reported at $50000.0 in Q1 2022.

For the quarter ending Q1 2022, Notes Payables changed N/A year-over-year to $50000.0; the trailing twelve-month figure through Mar 2022 stood at $50000.0 (changed N/A YoY), and the FY2021 full-year result was $50000.0, changed 0.0% from the prior year.
Notes Payables held at $50000.0 in Q1 2022, from $50000.0 in the prior quarter.
In the past five years, Notes Payables ranged from a high of $50000.0 in Q4 2020 to a low of $50000.0 in Q4 2020.
A 3-year average of $50000.0 and a median of $50000.0 in 2020 frame the typical range for Notes Payables.
Peak annual rise in Notes Payables reached 0.0% in 2021, while the deepest fall reached 0.0% in 2021.
Tracing IMMX's Notes Payables over 3 years: stood at $50000.0 in 2020, then changed by 0.0% to $50000.0 in 2021, then changed by 0.0% to $50000.0 in 2022.
Business Quant data shows IMMX's Notes Payables at $50000.0 in Q1 2022, $50000.0 in Q4 2021, and $50000.0 in Q4 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Immix Biopharma	487.25 Mn	487.25 Mn	-

Download Data